SCHEMBL4892996

SCHEMBL4892996

O=C(Nc1ccc(-c2ccc3ncnc(Nc4ccc(N5CCOCC5)cc4)c3c2)cc1)OCc1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PI4KB Q9UBF8 1/20 0.57
MAPT P10636 3/20 0.55
MAPK1 P28482 2/20 0.55
AHR P35869 1/20 0.55
HTT P42858 1/20 0.55
PRKDC P78527 1/20 0.53
BRAF P15056 3/20 0.49
RAF1 P04049 2/20 0.49
ALDH1A1 P00352 4/20 0.49
USP2 O75604 2/20 0.49
EGFR P00533 5/20 0.47
ERBB2 P04626 2/20 0.47
AURKA O14965 2/20 0.47
AURKB Q96GD4 2/20 0.47
NPSR1 Q6W5P4 1/20 0.47
PIK3CA P42336 1/20 0.47
PIK3CG P48736 1/20 0.47
FYN P06241 2/20 0.46
SRC P12931 2/20 0.46
VCP P55072 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4886091 0.86 EGFR (0.62) PI4KBMAPTMAPK1AHRHTT
SCHEMBL14026142 0.84 MAPK1 (0.72) PI4KBMAPTMAPK1AHRHTT
SCHEMBL4884813 0.83 MAP4K4 (0.59) PI4KBMAPTMAPK1AHRHTT
SCHEMBL4885395 0.82 MAPK1 (0.64) PI4KBMAPTMAPK1AHRHTT
SCHEMBL4891690 0.82 MAPK1 (0.59) PI4KBMAPTMAPK1AHRHTT
SCHEMBL4008515 0.81 MAPT (0.80) PI4KBMAPTMAPK1AHRHTT
SCHEMBL17075840 0.81 EGFR (0.59) PI4KBMAPTMAPK1AHRHTT
SCHEMBL78438 0.80 SMN1; SMN2 (0.67) MAPTPRKDCALDH1A1USP2NPSR1
SCHEMBL4007152 0.78 MAPK1 (0.72) PI4KBMAPTMAPK1AHRHTT
SCHEMBL4891326 0.78 PI4KB (0.54) PI4KBMAPTMAPK1AHRHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080311076-A1 Morpholinylanilinoquinazoline Derivatives For Use As Antiviral Agents ARROW THERAPEUTICS LIMITED (GB) 2008-12-18 US disclosed
EP-1748991-A1 MORPHOLINYLANILINOQUINAZO- LINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS Arrow Therapeutics Limited (GB) 2007-02-07 EP disclosed
WO-2005105761-A1 MORPHOLINYLANILINOQUINAZO- LINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS ARROW THERAPEUTICS LIMITED (GB) 2005-11-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080311076-A1 Morpholinylanilinoquinazoline Derivatives For Use As Antiviral Agents EIF2AK2, MAVS, IRF3 PI4KB 739/4885MAPT 2064/4885MAPK1 1945/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.